Advertisement

Topics

BeFutur (Suisse) S.A. Company Profile

18:18 EDT 19th September 2018 | BioPortfolio

Considering the vast impact caused by the emergence of the biotechnologies, and eager to play a driving role in these evolutions, BeFutur Biotechnologies and its subsidiaries have set up an exclusive center in Europe, specialized in the culture of cells and tissues for therapeutic purposes. During the last 10 years, BeFutur has developed through own funding, its entire technology. This latter innovates on the market of biotechnologies while bringing a complete and safe response to the practice of the culture of cells and tissues for human clinical applications. To date the phase of research and development in the fields of cardiology, bio-cosmetic, aesthetic medicine and parodontology is finished, and BeFutur is fully operational, technically speaking, for the industrial phase and the marketing

Location

14, chemin des Clochettes
Geneva
1206
Switzerland

Contact

Phone: (41) 22 - 800 33 10
Fax: (41) 22 - 800 33 13
Email: info@befutur.com


News Articles [69 Associated News Articles listed on BioPortfolio]

Credit Suisse: FDA won't approve Teva's migraine drug this month

Credit Suisse has downgraded Teva saying that the risk-reward ratio for an investment is unattractive.

MICROSCOPE BINOCULAIRE ANCIEN ” KERN AARAU “. MADE IN SUISSE.

25,50 EUR (2 Enchères)Date de fin: jeudi avr.-5-2018 19:16:08 CESTEnchérir | Ajouter à vos Affaires à suivre Biotech365 : MICROSCOPE BINOCULAIRE ANCIEN ” KERN AARAU “. MADE IN SUI...

Credit Suisse belässt Microsoft auf 'Outperform'

Die Schweizer Bank Credit Suisse hat die Einstufung für Microsoft vor Zahlen zum vierten Geschäftsquartal auf "Outperform" mit einem Kursziel von 115 US-Dollar belassen. Die positive Dynamik des C.....

Credit Suisse lässt GlaxoSmithKline auf 'Neutral'

Die Schweizer Bank Credit Suisse hat die Einstufung für GlaxoSmithKline vor Zahlen auf "Neutral" mit einem Kursziel von 1450 Pence belassen. Der Markt bei Atemwegserkrankungen sei seit dem Ausblic...

Credit Suisse lässt Microsoft auf 'Outperform'

Die Schweizer Bank Credit Suisse hat die Einstufung für die Aktien des Softwarekonzerns Microsoft auf "Outperform" mit einem Kursziel von 125 US-Dollar belassen. Dies schrieb Analyst Brad Zelnick ...

Credit Suisse belässt Gerresheimer auf 'Outperform'

Die Schweizer Bank Credit Suisse hat die Einstufung für Gerresheimer nach Zahlen zum ersten Geschäftsquartal auf "Outperform" mit einem Kursziel von 72 Euro belassen. Das Zahlenwerk des Verpackung.....

ANALYSE-FLASH: Credit Suisse belässt Microsoft auf 'Outperform'

Die Schweizer Bank Credit Suisse hat die Einstufung für Microsoft vor Zahlen zum vierten Geschäftsquartal auf "Outperform" mit einem Kursziel von 115 US-Dollar belassen. Die positive Dynamik des C.....

Credit Suisse belässt Astrazeneca auf 'Outperform'

Die Schweizer Bank Credit Suisse hat die Einstufung für Astrazeneca auf "Outperform" mit einem Kursziel von 5800 Pence belassen. Nach einer Reihe an Patentabläufen befinde sich der Pharmaherstelle.....

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Cellular radiance spf 30 [La Prairie, Inc.]

Cellular Radiance Emulsion SPF 30

Asacol [Cardinal Health]

Asacol (mesalamine)Delayed-Release Tablets

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Oral Nutritional Supplements Compared With Standard Diet in Postoperative Gastric Cancer Patients With Adjuvant Chemotherapy

Background: It is known that postoperative malnutrition remains inevitable for gastric cancer patients with adjuvant chemotherapy, which could have prejudicial influence on the compliance ...

Companies [5 Associated Companies listed on BioPortfolio]

BeFutur (Suisse) S.A.

Considering the vast impact caused by the emergence of the biotechnologies, and eager to play a driving role in these evolutions, BeFutur Biotechnologies and its subsidiaries have set up an exclusive ...

Resaphene Suisse AG

Resaphene Suisse AG was founded in 2015 with the aim of developing a tinnitus therapy device with funds from the incubator of BS Health Group AG. After the prototype was available...

Gen Suisse

Nil

Credit Suisse

We were one of the first investment banks to create specialized global industry groups, each dedicated to providing unmatched industry knowledge to its clients. Each industry is covered by senior prof...

Renaissance Capital Milestones

Renaissance Capital, founded in 1991 and headquartered in Greenwich, CT, is the leading provider of independent research and investment management services focused on newly public companies. The Firm ...

More Information about "BeFutur (Suisse) S.A." on BioPortfolio

We have published hundreds of BeFutur (Suisse) S.A. news stories on BioPortfolio along with dozens of BeFutur (Suisse) S.A. Clinical Trials and PubMed Articles about BeFutur (Suisse) S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BeFutur (Suisse) S.A. Companies in our database. You can also find out about relevant BeFutur (Suisse) S.A. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...


Corporate Database Quicklinks



Searches Linking to this Company Record